Tag: SynCardia Total Artificial Heart
-
Picard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies
— Independent dual motor ventricular design demonstrates stable full circulatory support across all study procedures — — Advancing second-generation Emperor TAH development toward a fully implantable system — TUCSON, Ariz., June 02, 2026 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (the “Company” or “Picard Medical”), parent company of SynCardia Systems LLC, maker of…
-
From Proven to Pioneering: SynCardia’s Next Leap in Artificial Heart Technology
Phoenix, AZ (November 12, 2025) – Tucson-based SynCardia Systems, LLC, the manufacturer of the SynCardia Total Artificial Heart, is a wholly owned subsidiary of Picard Medical, Inc. Picard Medical became a publicly traded company on August 29, 2025, and completed its Initial Public Offering (IPO) on September 2, 2025, raising approximately $19.5 million in gross…
-
Picard Medical, Inc. Announces Pricing of $17 Million Initial Public Offering
TUCSON, ARIZONA, August 28, 2025 — Picard Medical, Inc. (“Picard” or the “Company”), a medical technology company that manufactures and sells the only total artificial heart (the “SynCardia Total Artificial Heart”, or “STAH”) approved by the U.S. Food and Drug Administration (“FDA”), and Health Canada, today announced the pricing of its initial public offering (the…
